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Abstract
Clostridium difficile (C. difficile) is a Gram-positive, spore-forming, anaerobic bacillus, which is widely distributed in the
intestinal tract of humans and animals and in the environment. In the last decade, the frequency and severity of C. difficile
infection has been increasing worldwide to become one of the most common hospital-acquired infections. Transmission of this
pathogen occurs by the fecal-oral route and the most important risk factors include antibiotic therapy, old age, and hospital or
nursing home stay. The clinical picture is diverse and ranges from asymptomatic carrier status, through various degrees of
diarrhea, to the most severe, life threatening colitis resulting with death. Diagnosis is based on direct detection of C. difficile
toxins in feces, most commonly with the use of EIA assay, but no single test is suitable as a stand-alone test confirming CDI.
Antibiotics of choice are vancomycin, fidaxomicin, and metronidazole, though metronidazole is considered as inferior. The goal
of this review is to update physicians on current scientific knowledge of C. difficile infection, focusing also on fecal microbiota
transplantation which is a promising therapy.
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Introduction
CDI has become one of the most significant
nosocomial infection
Clostridium difficile (C. difficile) is a Gram-positive, anaero-
bic, spore-forming, toxin-producing bacillus, which was offi-
cially renamed in 2016 to Clostridioides difficile. New name
reflects the taxonomic differences between this species
and other members of the Clostridium genus [1, 2].
Spores of C. difficile are transmitted by the fecal-oral
route, and the pathogen is widely present in the envi-
ronment. Potential reservoirs for C. difficile include
asymptoma t i c ca r r i e r s , i n f ec t ed pa t i en t s , t he
contaminated environment and animal intestinal tract
(canine, feline, porcine, avian). Approximately 5% of
adults and 15–70% of infants are colonized by
C. difficile, and the colonization prevalence is several
times higher in hospitalized patients or nursing home
residents [3]. C. difficile was first isolated from a
healthy newborn’s stool in 1935 by Hall and O’Toole
[4]. Until the 1970s, it was considered as a microorgan-
ism that is rarely, but present in normal intestinal mi-
crobiota. After the introduction of antibiotics, the role of
C. difficile in the pathogenesis of large intestine diseases
increased. In 1974, Tedesco et al. found that 21% of
patients treated with clindamycin developed diarrhea.
Pseudomembranes were found in 50% of cases, as
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revealed by further endoscopic examination [5]. At the
end of the twentieth century, the incidence of
Clostridium difficile infection (CDI) markedly increased.
Currently, CDI has become one of the most significant
nosocomial infections, which affects all hospital wards.
Risk factors associated with CDI
Antibiotic exposure, older age, and hospitalization
are key factors for CDI development
Significant patient-related risk factors for CDI are antibi-
otic exposure, older age, and hospitalization. Nearly every
antibiotic has been associated with the development of
CDI, including the drugs used for treatment of CDI: met-
ronidazole and vancomycin. Broad spectrum penicillins
and cephalosporins, clindamycin, and fluoroquinolones
possess a higher risk for CDI induction than other antibi-
otics [3]. The risk for development of CDI is 8- to 10-fold
higher during antimicrobial therapy and 4 weeks thereaf-
ter, and 3-fold higher in the next 2 months [6]. Patient
age > 65 years increases the risk for CDI 5 to 10-fold,
compared with patients < 65 years of age. Nonetheless, a
significant proportion of CDI occurs in a younger popula-
tion. Age > 65 years is a significant risk factor not only for
CDI itself, but also for poor clinical outcome including
severity and mortality [3, 7]. Although most cases of
CDI are linked to healthcare exposure, either hospitaliza-
tion or nursing home stay, recent studies suggest that the
incidence of community-acquired CDI is growing, and
might have recently reached up to 30% of all CDI cases
[8]. The percentage of hospitalized patients with
C. difficile colonization differs by country, patient age
group, and length of hospitalization. During the first days
of hospitalization, the incidence of C. difficile colonization
ranges from 2.1 to 20% [9–13], and increases with longer
hospital stay, e.g., from 20 to 45.4% in a study by Huang
et al., from 2.1 to 50% after 1 month of hospitalization in a
study by Clabots et al., and from 1 to 50% after > 1 month
of hospitalization in a study by Johnson et al. [12, 14, 15].
It must be noted that colonization does not necessarily
mean symptomatic infection; it is suggested that only
25–30% of asymptomatic colonized patients develop diar-
rhea. C. difficile spores survive in the environment for
several months [16]. Toilets, clinic furnishings, phones,
and medical devices (thermometers, stethoscopes) may
all serve as reservoirs for the C. difficile spores. The
spores can be transferred to patients via the hands of
healthcare personnel; therefore, good hand hygiene with
soap and water and regular vinyl glove use is crucial to
interrupt the transmission, as demonstrated by Johnson
et al. [17]. Nursing home residents are at higher risk for
CDI than the overall population, but lower than hospital-
ized patients (15%). This is mainly due to older age, co-
morbidities, more frequent hospitalizations, and more fre-
quent antibiotic therapy in this group compared to the
non-institutionalized population. C. difficile is the most
common cause of nosocomial diarrhea [18]. It has been
postulated that gastric acid suppression may have an in-
fluence on CDI development, but subsequent analysis ad-
justed for other comorbidities did not confirm this hypoth-
esis [19, 20]. This is in line with the observations that
gastric acid did not kill the C. difficile spores [3].
Nonetheless, this topic remains controversial, as several
studies and meta-analyses have found a significant associ-
ation [21–23], whereas other have failed to associate pro-
ton pump inhibitors use with risk of CDI development
[24–26].
Other well-defined risk factors for CDI include inflamma-
tory bowel disease, gastrointestinal surgeries, immunological
incompetence caused by malignant neoplasms, transplanta-
tions, chronic kidney diseases, or immunosuppressant use
[3, 27].
Pathogenesis
The main protective barrier against CDI is the normal
intestinal microflora
Infection with C. difficile mostly occurs as a result of spore
transmission. Spores are resistant to heat, acid, and antibiotics.
The main protective barrier against CDI is the normal intesti-
nal microflora. After reaching the intestine, bile acids play an
important role in the induction of C. difficile spore germina-
tion [28]. Bile acids are cholesterol derivatives produced and
transformed in the liver. They facilitate the absorption of fats
and fat soluble vitamins in the intestine. They support diges-
tion, improve gastrointestinal motility, and actively affect bac-
terial flora [29, 30]. We distinguish between primary and sec-
ondary bile acids. Primary bile acids, cholic acid and
chenodeoxycholic acid, are synthesized in the liver from cho-
lesterol and are secreted into the intestine after eating. Then, as
a result of active transport, about 95% of primary bile acids are
reabsorbed in the final part of the intestine. The remaining,
non-reabsorbed bile acids may undergo 7a-dehydroxylation
by gut bacteria, transforming into secondary bile acids,
deoxycholic acid and lithocholic acid [30]. In vitro, primary
bile acids generally stimulate germination of C. difficile
spores; the secondary bacteria inhibit this process [31, 32].
Moreover, in patients with CDI, there are changes in the fecal
content of bile acids. Allegretti et al. showed a higher concen-
tration of secondary bile acids in the feces of healthy people
compared to CDI, while primary bile acid concentration was
higher in patients with recurrent CDI compared to patients
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with their first episode of infection [33]. However, it has to be
reinforced that the influence of bile acids is likely more com-
plex than the simple model where primary bile acids strictly
promote and secondary bile acids inhibit C. difficile germina-
tion and vegetation as described in the excellent review by
Baktash et al. [29].
When the balance of gut microorganisms is disrupted,
C. difficile starts to dominate and colonize the large intestine
which might be the first step of infection. As mentioned pre-
viously, only a portion of colonized patients will develop
symptoms of CDI [3]. The pathogen is not invasive, and vir-
ulence is mostly due to enzymes, such as collagenase, hyal-
uronidase, chondroitin-sulfatase, as well as toxins, which
damage the epithelial cell cytoskeleton, leading to disruption
of tight junctions, fluid secretion, neutrophil adhesion, and
local inflammation. The result is a breakdown of gut barrier
integrity and loss of functionality [29, 34]. C. difficile pro-
duces two important in disease pathogenesis types of toxins,
A and B, which are both enterotoxic and cytotoxic; however,
traditionally, toxin A is named Benterotoxin A^ and toxin B,
Bcytotoxin B.^ C. difficile transferase (CDT; or binary toxin)
is a third toxin produced by someC. difficile strains, including
the epidemic PCR ribotypes 027. It probably can form
microtubule-based protrusions on epithelial cells, which the-
oretically could have a clinical impact. There are reports of
severe CDI development caused by the TcdA−TcdB−CDT+
strain [35].
Toxins are transported to the cell cytoplasm, where they
inactivate the Rho family of GTPases. The Rho protein takes
part in actin polymerization, and therefore stabilizes the cell
cytoskeleton. As a result of Rho protein inactivation, the in-
flammatory process intensifies. In more severe cases,
microulcerations covered with pseudomembranes (composed
of destroyed intestinal cells, neutrophils, and fibrin) start to
occur on the intestinal mucosal surface. Initial studies on an-
imal models suggested that toxin A plays a dominant role, and
the action of toxin B may occur only via the tissue damage
caused by toxin A [36]. However, in studies involving human
colonic tissue, TcdB was a potent inflammatory toxin, where-
as TcdAwas even weaker, and both toxins were able to elicit
CDI symptoms independently [36–38].
The C. difficile BI/NAP1/027 strain is hypervirulent and
resistant to fluoroquinolones, exhibits intensive spore produc-
tion, and is responsible for the most severe CDI cases. The
C. difficile BI/NAP1/027 epidemic strain is characterized by
two mutations in the toxin regulatory gene tcdC, an 18 base-
pair (bp) deletion, and deletion at position 117, which leads to
increased production of toxins A and B [3, 39]. It was first
isolated at the beginning of the twenty-first century in North
America and Europe. BI/NAP1/027 was extremely rare before
2000; in the first two large epidemics of CDI in North
America at the beginning of the last decade, the percentage
of CDI caused by BI/NAP1/027 was 51% in the US and 84%
in Canada [39, 40]. Analyzing the data of 6000 CDI cases
prior to 2001, only 14 cases attributed to BI/NAP1/027 were
identified, representing only 0.2% of all cases [40].
Furthermore, numerous cytokines play a role in CDI patho-
genesis, including IL-8, IL-1β, IL-6, TNFα, INFγ, and leu-
kotriene B4 [41–43].
Clinical manifestation
CDI clinical picture can vary from the asymptomatic
carrier state to life-threatening colitis resulting
with death
The clinical picture of CDI is very heterogenous, and ranges
from the asymptomatic carrier state, mild or moderate diar-
rhea, to life-threatening fulminant colitis. Although the incu-
bation period is not precisely defined, and some reports sug-
gest 2–3 days, more recent studies demonstrate that the incu-
bation period might be even longer than 3 days and is very
individual-dependent [44–47]. CDI can affect every part of
the colon, but the distal segment is most commonly infiltrated.
Most patients with CDI suffer from mild diarrhea and experi-
ence recovery spontaneously after 5–10 days of antibiotic
therapy withdrawing. Diarrhea occurs in most cases during,
or directly after antimicrobial therapy, although CDI onset
might be also a couple of weeks afterwards. The clinical fea-
tures of CDI, in addition to watery diarrhea, include abdomi-
nal pain, fever, nausea and vomiting, weakness, and loss of
appetite. Fecal occult blood test is often positive, although
active bleeding is rarely present [47]. In the most severe clin-
ical presentation of CDI, symptoms are life-threatening, and
include significant dehydration, abdominal distension, hypo-
albuminemia with peripheral edema, and subsequent circula-
tory shock. Other severe complications of CDI include toxic
megacolon, colon perforation, intestinal paralysis, kidney fail-
ure, systemic inflammatory response syndrome, septicemia,
and death [47]. Extracolonic manifestations of CDI are rare,
and most commonly involve small intestine infiltration, reac-
tive arthritis, and bacteremia [43]. Mortality rate directly due
to CDI is estimated at 5%, whereas mortality associated with
CDI complications reaches 15–25%, and up to 34% in inten-
sive care units (ICU). Mortality doubles in ICU patients with
CDI, as compared with ICU patients without CDI [7, 48, 49].
Poor outcome is associated with older age, high leukocytosis,
hypoalbuminemia, and high creatinine level [43, 50]. It has
been also shown that first-ever CDI episode increases the
overall risk of death [7].
CDI relapse of symptoms occur most commonly during
the first week after the initial episode when treatment is
complete. After effective treatment of first CDI episode, at
least one new recurrent episode occurs in 10–25% of pa-
tients, and up to 65% in patients who experienced already
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> 1 recurrent CDI [51, 52]. There is evidence to show that
half of the recurrent CDI cases are due to relapses of
infection with the original strain, whereas the other half
is caused by re-infection with different strains. Impaired
immune response to C. difficile toxins, as well as new
exposure to spores, is thought to contribute to recurrences.
Antibiotic resistance does not seem to influence the risk of
recurrences [18, 43, 53].
Prevention
Prevention strategies should be implemented
in every suspected case, not only in confirmed
patients
Strategies for prevention of CDI include the use of gloves and
disposable gowns by healthcare personnel and visitors during
the whole diarrheal episode. After every direct contact with a
CDI-patient, everyone should wash their hands with soap and
water. Alcohol-based hand hygiene products do not damage
the C. difficile spores, whereas the mechanical hand washing
with the use of running water and soap prevents spread of the
spore. Optimally, every patient with CDI should be isolated in
a single room. If this is not possible, contact between patients
should be avoided, (e.g., reading the same books/magazines,
using the same phone), and the patient should have his or her
own furnishing. There are no current recommendations to
screen asymptomatic carriers, as effectiveness has not been
proven. Chlorine-based solutions are commonly recommend-
ed for environmental cleaning, with 1000 ppm of chlorine
concentration being effective, and 5000 ppm being the most
optimal choice [54]. Prevention strategies should be imple-
mented in every suspected case, not only in confirmed pa-
tients. After discharge, the patient’s room should be carefully
decontaminated [3].
Diagnosis
No single test is suitable as a stand-alone test
confirming CDI
CDI should first be considered when diarrhea symptoms are
present (≥ 3 loose stools during 24 h). The diagnosis of CDI is
based on detection of C. difficile toxins directly in a stool
sample, most commonly with an enzyme immunoassay
(EIA), which provides rapid turnaround time (about 1–2 h),
as well as sensitivity of 75–85% and specificity of 95–100%.
Because of its low cost and ease of use, this is the most pop-
ular test in all laboratories. Tests detecting C. difficile antigens
are based on the detection of glutamate dehydrogenase (GDH)
and are characterized by ease of use and rapid turnaround time
as well as a specificity of almost 100%. However, they do not
distinguish whether the strain is toxigenic (specificity of 59%)
[18, 55]. It should be pointed out that old-generation assays
(using latex agglutination) had sensitivity of 58–68% and
specificity of 89–99%. In 2009, tests that use amplification
of nucleic acid (NAAT, nucleic acid amplification test) were
introduced. They are based on either a PCR method or iso-
thermal amplification. NAAT have higher sensitivity (80–
100%) and specificity (87–99%) compared to an EIA test.
The specificity is especially high, reaching 95%, when a neg-
ative result is obtained. In this situation, another cause of di-
arrhea should be considered [47, 56, 57]. The NAAT have also
limitations, namely, high cost and some interpretation difficul-
ties. PCR detects the presence of a toxin encoding gene, thus
confirms the presence of C. difficile toxin-producing strain,
but it does not necessarily mean that the strain produces any
toxins at the moment. If the diarrhea is of other origin, detec-
tion of such strain would become misleading, as it would
pursue further treatment towards CDI. Persistent and often
ineffective treatment of only colonized patients does not im-
prove their clinical situation. When dealing with such diag-
nostic difficulties, comprehensive diagnostic evaluation of
other potential diarrhea causing disorders is required. A cyto-
toxic assay test (CYTA) is not routinely used in microbial
culture due to its slow turnaround time and lack of standard-
ization (48–72 h) [3, 47].
According European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) guidance, no single
test is suitable as a stand-alone test confirming CDI.
The best way to optimize diagnosis of CDI is to com-
bine two tests in algorithm. The first test should be a
test with high negative predictive value (it can either be
a GDH EIA or NAAT). The second test should be a test
with a high positive predictive value (it is toxin A/B
EIAs). If the first test is negative, it excludes CDI. If
the first test is positive, the second test (toxin A/B
EIAs) should be performed. If the second test is posi-
tive, it confirms CDI. If the second test is negative, the
case needs to be clinically evaluated, and such result
can be seen in three situations: CDI with toxin levels
below the threshold of detection, false-negative toxin A/
B EIA result, or C. difficile carriage. Samples with a
negative GDH result but that are positive for toxin need
to be retested, as this is an invalid result [58]. Flow
chart of CDI diagnosis is presented on Fig. 1.
Proper management in the pre-analytical phase is extreme-
ly important, as the toxin present in a stool sample is easily
degraded at room temperature, and after about 2 h, it can be no
longer detected in the acquired material. Once the stool sam-
ple is obtained, it should be stored at refrigerator temperature
(+ 4 °C) and used for testing within the next 24 h [59]. The test
is only performed on diarrheal sample unless ileus is
suspected—in such case, it is acceptable to obtain a sample
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by rectal swab. With the exception of epidemiological pur-
poses, it is not recommended to test stool samples obtained
from asymptomatic patients. It is also not recommended to
repeat testing for C. difficile after successful treatment is com-
pleted as there is a significant proportion of patients who test
positive and their treatment does not need to be continued or
repeated [18, 54, 60].
Endoscopic evaluation is also useful; however, it
should be emphasized that it is not performed in patients
with uncomplicated CDI that was confirmed with immu-
nological tests. Endoscopy is indicated if diagnostic
problems occur, namely, a typical CDI presentation with
negative C. difficile test results, no response to standard
course of antibiotics or when an alternative diagnosis is
suspected, and direct visualization and/or biopsy of the
bowel mucosa is needed. If the colonoscopy is per-
formed, limited flexible sigmoidoscopy is preferred with
minimal or no air insufflation to avoid perforation of the
inflamed colon. The pseudomembranes found during the
procedure are elevated, white to yellow lesions, typically
about 2 cm in diameter, which are irregularly distributed
and separated by normal mucosa. They are not removed
by intes t ina l wal l r ins ing. The dis t r ibut ion of
pseudomembranes tends to vary. Not all patients with
CDI have pseudomembranes, and their absence does
not rule out C. difficile infection. For example,
pseudomembranes are rarely in recurrent CDI or in CDI
among patients with inflammatory bowel disease
[61–63]. On the other hand, pseudomembranous colitis
can be caused by a number of different etiologies, like
Behcet’s disease, collagenous colitis, inflammatory bowel
disease, ischemic colitis, and also other infections, like
CMV or enterohemorrhagic Escherichia coli O157:H7
[64].
Abdominal imaging (X-ray, ultrasound) in patients with
CDI reveals distended bowel loops, often with wall thicken-
ing. Their use is of the highest importance when diagnosing
CDI complications. Ultrasound imaging is an especially
good method of monitoring the width of colon [18, 43].
Computed tomography of the abdomen and pelvis with
oral and intravenous contrast is useful among patients
with severe CDI, helping to evaluate for presence of
toxic megacolon, bowel perforation, or other findings
warranting surgical intervention [65].
Patient with symptoms
of CDI
negative result
CDI excluded CDI confirmed positive result
positive result toxin A/B EIA negative result
Possible: 
- CDI with toxin levels below the 
threshold of detection 
- false-negative toxin A/B EIA result 
- C. diff. carriage.
Start testing and also start patient isolation
testing: NAAT or GDH EIA
Patient with no  
symptoms of CDI
Do not test
clinical 
evaluation
Fig. 1 Flow chart of CDI diagnosis
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Laboratory findings reveal high leukocytosis, elevated C-
reactive protein, and in the most severe cases hypoalbumin-
emia as well as acute kidney injury [43].
CDI treatment
Vancomycin and fidaxomicin are the cornerstone
of CDI treatment
Treatment should only be started in patients with CDI symp-
toms; presence of the C. difficile toxin without symptoms of
the infection is not an indication for treatment. In 2014, the
ESCMID guidelines were published in which two drugs met-
ronidazole and vancomycin were the cornerstone of CDI treat-
ment. Metronidazole was first-line drug in non-severe CDI,
while vancomycin was the drug of choice for severe CDI [66].
Since then, the results of two identical, phase 3, multicenter,
randomized, double dummy, double-blind, active-controlled,
parallel-design efficacy studies (RCT) showed superiority of
vancomycin relative to metronidazole. Clinical success oc-
curred in 210 (81%) of 259 patients treated with vancomycin
versus 202 (73%) of 278 patients who were treated with met-
ronidazole (p = 0.02). However, among patients with severe
disease, a statistically significant relationship was not
achieved (clinical success achieved 78.5% in the vancomycin
group compared with 66.3% in the metronidazole group (p =
0.059) [67]. In 2017, meta-analysis by Nelson et al. also con-
cluded that metronidazole is inferior compared to vancomycin
in the treatment of CDI [68].
Fidaxomicin is a drug that has been available since 2011. It
is a macrocyclic, bactericidal antibiotic of narrow spectrum,
directed primarily against Gram-positive pathogens. It has
high efficacy against C. difficile, with no significant influence
on the physiological flora of the colon. Fidaxomicin has effi-
cacy comparable to vancomycin and in some groups higher
effectiveness in reducing CDI recurrence. CDI recurrence af-
ter treatment of the first episode with fidaxomicin occurred in
15% of patients compared to 25% of patients treated with
vancomycin. However, the same reduction in recurrence of
the BI/NAP/027 strain was not observed [69, 70].
Fidaxomicin is also associated with lower percentage of CDI
recurrence than vancomycin (20% vs 36%) in patients, who
experienced CDI recurrence > 4 weeks after the treatment of
the previous episode [71]. Another published meta-analysis
suggested that fidaxomicin may be considered as first-line
therapy for CDI [72]. Moreover, Guery et al. in 2017 showed
that a tapered fidaxomicin treatment (days 1–5, 200 mg two
times a day, followed by once daily on alternating days during
days 7–25) is superior (p = 0.03) than vancomycin (125 mg
oral capsules, four times daily on days 1–10) in resulting in a
sustained clinical cure (30 days after end of treatment) in CDI.
Recurrence rate at 90 day was also lower among fidaxomicin
arm then vancomycin arm (9% vs 18%, respectively, p =
0,048) [73].
In 2017, Infectious Diseases Society of America (IDSA)
and Society for Healthcare Epidemiology of America (SHEA)
updated their guidelines, pointing that vancomycin and
fidaxomicin are the cornerstone of CDI treatment [47]
(Table 1).
There are no uniform criteria stratifying non-severe and
severe CDI. Based on the commonly known risk factors for
CDI severity and CDI criteria used by other researchers, we
have proposed to define the severity of CDI as follows.
Severe CDI presents with or develops two or more of the
following severity markers during the course of the disease:
hypoalbuminemia (serum albumin < 3 g/dl), white blood cell
count ≥ 15,000 cells/mm3, creatinine > 1.5 × baseline (or glo-
merular infiltration rate reduced by 25% from baseline), or tem-
perature > 38.5 °C. Fulminant (severe complicated CDI), de-
fined as CDI that presents with or develops at least one of the
following signs or symptoms: admission to an intensive care
unit, hypotension with or without use of vasopressors, ileus,
toxic megacolon, mental status changes, serum lactate levels
> 2.2 mmol/l, or any evidence of end organ failure [74].
If there is high suspicion of CDI with a negative ELISA
assay, it is reasonable to start empiric antibiotic therapy for
CDI. Other antibiotics that show activity against C. difficile
include teicoplanin, tigecycline, bacitracin, and nitazoxanide.
However, they are not included in CDI treatment recommen-
dations and they may be considered when basic therapeutic
options have run out. Pregnant and breast-feeding women
should be treated with orally administered vancomycin in typ-
ical doses [3, 75–77]. The use of additional antibiotics (other
than those treating CDI) is associated with increased risk of
prolonged diarrhea and CDI recurrence, which is why they
should be discontinued. However, if such therapy is indis-
pensable, it should be continued preferably with antibiotics
that are associated with lower risk of CDI, such as macrolides,
aminoglycosides, sulfonamides, vancomycin, or tetracyclines.
Some authors suggest that in this situation, prolonged treat-
ment with antibiotics acting against C. difficile should be
discontinued a week after the other broad-spectrum therapy
is completed [78, 79]. According to authors of this paper, such
regimen is worth implementing, if the additional CDI treat-
ment does not exceed 7 to 10 days.
The role of probiotics in the treatment and prevention of
CDI is completely unknown. Three large trials, including a
meta-analysis have shown a positive effect of probiotics in
the prevention of primary CDI. However, it should be empha-
sized that the meta-analysis has a variety of limitations. The
studies included in the meta-analysis differ in regard to doses
and types of probiotics, C. difficile strains, doses and types of
antibiotics, time of therapy, and ultimately in some of these
studies the number of CDI was very low in all study arms.
Considering the pathophysiology of CDI, it appears that
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probiotics may be a part of CDI prevention or treatment; how-
ever, we still lack properly randomized studies addressing this
problem [50, 80–84]. There are insufficient data at this time to
recommend administration of probiotics for primary, second-
ary prevention or treatment of CDI [47, 66].
AsymptomaticC. difficile carriers have high concentrations
of antibodies directed against toxins A and B [85]. Based on
this knowledge, there are studies on intravenous administra-
tion of immunoglobulins as well as monoclonal antibodies
that may be useful in both the treatment and prevention of
CDI recurrences. Successful immune therapy for the treatment
or prevention of CDI would be an interesting way of fighting
the disease, as in contrast to vancomycin, metronidazole, and
fidaxomicin, it would not disrupt the bacterial flora of the host
[86]. Anti-toxin antibodies are of great importance in the de-
velopment of immunity against CDI. It has been shown that
naturally produced anti-toxin antibodies in C. difficile colo-
nized patients who did not develop diarrhea have protective
effects [87, 88]. The administration of monoclonal antibodies
directed against these toxins markedly reduced the risk of CDI
recurrence. Thus, there is a chance that in the near future, we
will have new forms of protection against C. difficile recur-
rence which might even be used when fighting the first infec-
tion [89]. Bezlotoxumab (a monoclonal antibody that binds to
Table 1 Antibiotic regimens used
in the treatment of C. difficile
infection [29, 47, 66, 67, 69–73]
First episode of the infection
Non-severe disease • Vancomycin 125 mg orally four times a day for 10 days
OR
• Fidaxomicin 200 mg orally twice a day for 10 days
• If above agents are unavailable: metronidazole 500 mg
orally three times a day for 10 days
Severe disease • Vancomycin 125 mg orally four times a day for 10 days
OR
• Fidaxomicin 200 mg orally twice a day for 10 days
Fulminant disease (previously
referred as severe complicated)
• Vancomycin 500 mg orally or via nasogastric tube four times a day
AND
• Metronidazole 500 mg IV 3 times a day + alternatively
If ileus is present: vancomycin per rectum (vancomycin 500 mg
in 100 ml saline as enema) four times a day* (10–14 days)
First recurrence
If the first episode was treated with metronidazole or fidaxomicin:
• Vancomycin 125 mg orally four times a day for 10 days
If the first episode was treated with vancomycin:
• Vancomycin pulsed-tapered orally (each dose 125 mg):
# Four times daily for 10–14 days and then
# Twice a day for 7 days, than
# Once a day for 7 days, than
# Every 2 or 3 days for 2–8 weeks
OR
• Fidaxomicin 200 mg orally twice a day for 10 days
Second of subsequent recurrences
• Vancomycin pulsed-tapered orally (regimen as above)
OR
• Fidaxomicin 200 mg orally twice a day for 10 days;
OR
• Vancomycin 125 mg orally four times a day for 10 days, followed
by rifaximin 400 mg three times daily for 20 days
OR
• Fecal microbiota transplantation
*If there is partial ileus, vancomycin should be administered both orally and rectally; if the ileus is complete, only
rectal vancomycin should be used. Rectal vancomycin administration is associated with a risk of large bowel
perforation, and should only be used in those patients who do not respond to oral therapy; some patients may have
delayed response to treatment and clinicians should consider extending treatment duration from 10 to 14 days in
such situations
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C. difficile toxin B) was approved by the FDA in 2016 for
prevention of recurrent CDI in patients with high risk of CDI
recurrence. The registration trial, which included over 2500
patients, showed that bezlotoxumab together with standard
oral antibiotic therapy was associated with a significantly low-
er rate of recurrent infection than oral antibiotic therapy alone
(17 versus 28%). At the same time, no similar effect was
shown for actoxumab (a monoclonal antibody that binds
to C. difficile toxin A). Bezlotoxumab is undoubtedly a
significant achievement in CDI prevention; however, its
use is limited by high cost and potential side effects. In
the group of patients treated with bezlotoxumab, the in-
cidence of acute decompensated heart failure was signif-
icantly higher when compared with the placebo group
(12.7% vs 4.8% respectively) [90].
Fecal microbiota transplantation
Fecal microbiota transplantation have the highest
rate of prevention of recurrent CDI among all
therapeutic options
The fecal microbiota transplantation (FMT) procedure has
been known for over 1000 years, and was first described
by a traditional Chinese medicine doctor Ge Hong, who
lived during the Dong Lin Dynasty period (284–364 BC).
He applied human fecal suspension orally to patients with
severe diarrhea or food poisoning [91]. In Europe, the idea
was first used in veterinary medicine by the Italian anato-
mist Fabricius Aquapendente in the seventeenth century
[92]. Modern medicine first performed fecal transplanta-
tion in 1958. Eiseman et al. used fecal enema as therapy
for pseudomembranous enterocolitis (C. difficile had not
been routinely identified at that time) [93]. The first report
about fecal transplantation in patient with confirmed
C. difficile infection was published in 1983 [94].
Nowadays, abnormal gut microbiota is considered a key
factor in CDI development. Relatively short antimicrobial
therapy might dramatically reduce the amount of intestinal
microbiota, but recovery may last several months. During that
specific period, patients lack their protective barrier, and with
exposure to spores an infection might develop quickly. Even
though the gut microbiota is composed of thousands of spe-
cies of microbes, it is thought that Bacteroides and Firmicutes
play predominant role in immunological responses against
C. difficile [95].
Antibiotic withdrawal together with FMT have the
highest rate of prevention of recurrent CDI among all
therapeutic options [96–98]. Nood et al. performed open-
label, randomized, controlled trial, which compared three
treatment regimens: the infusion of donor feces preceded
by an abbreviated regimen of vancomycin and bowel
lavage, a standard vancomycin regimen, and a standard
vancomycin regimen with bowel lavage. The study was
stopped after an interim analysis. Eighty-one percent of
the patients in FMT group had resolution of CDI compar-
ing with only 31% patients receiving vancomycin alone
and 23% receiving vancomycin with bowel lavage
(p < 0.001 comparing with both control group) .
Moreover, no significant differences in adverse events
among the three study groups were observed except for
mild diarrhea and abdominal cramping in the FMT group
on the infusion day. After FMT, patients showed increased
fecal bacterial diversity, similar to that in healthy donors
[98]. One hundred percent effectiveness was observed in
the 27-patient study by Dutta et al. where fecal material
was directly introduced into small and large intestine [96].
Louie et al. performed interesting experiments with fecal
microbes contained in gelatin capsules. According to the
protocol, 27 patients received 24–34 capsules, and the
effectiveness of the therapy was also 100% [97].
Transplantation with frozen fecal material, first de-
scribed by Borody and Khoruts, simplified the procedure
[99]. Stool samples can be stored at − 80 °C and used
during next 5–6 months. Some stool banks extend storing
period for 2 years [100]. FMT procedure has not yet been
standardized. The donated stool is mixed with normal sa-
line solution, homogenized, and filtrated to separate the
solid parts, to obtain fluid material. Fecal transplant can
be administrated via oral capsules, lower gastrointestinal
(GI) tract procedure (colonoscopy, retention enema), or
upper GI tract procedure (nasojejunal/nasoduodenal tube)
[101]. Some potential complications of FMT are connect-
ed with delivery method (e.g., perforation with colonosco-
py, aspiration pneumonia with upper GI administration).
However, the frequency of complications associated with
FMT is likely similar to the frequency of complications
when these procedures are performed for other indica-
tions. It seems that the effectiveness of FMT is higher after
lower GI tract administration when compared to upper GI
tract administration [101]. Retention enema is a procedure
with a low cost, easily accessible, and with relatively low
risk of complications; however, it may be difficult to
maintain stool transplant and in such a situation, patients
require repeated enema [101]. FMT is highly promising
treatment of CDI, and several large Bfeces banks^ have
been developed. In the Netherlands, treatment with FMT
is organized at a national level by the BNetherlands Donor
Feces Bank^ (NDFB, https://www.ndfb.nl/) at Leiden
University Medical Center. Since 2016, NDFB has
received more than 120 requests for treatment of FMT
for patients with recurrent CDI. Each request is
discussed by a panel of experts comprising of medical
microbiologists, gastroenterologists, and infectious
disease physicians. Of all received requests, only 80%
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fulfilled to the criterium of recurrent CDI and were
treated. The success rate was very high, more than 90%,
and clearly associated with the stringent inclusion criteria
(E.T Terveer,. K.E Vendrik and E.J.Kuijper, manuscript in
preparation). Two main concerns are the risk of
transferring infectious pathogens from the donor to the
recipient, and development of autoimmunological
disorders. Although the possibility of infecting the
recipient with fecal material still exists, it is minimalized
by proper donor screening. Potential donors should be
healthy, have daily formed bowel movement, and
screened for bacterial, viral, and parasites infection, as it
is presented in thorough Terveer et al. study [100]. The
influence of gut microbiota on some immune-mediated
diseases such as irritable bowel disease raises concerns
about long-term side effects of fecal transplantation. This
field merits further investigation in the future [86].
Conclusion
In the past decade, CDI became one of the most detrimental
nosocomial infections. It is of most importance to remember that
CDI prevention starts with healthcare professional education re-
garding such preventive measures, as hand washing, gloves
wearing, proper decontamination of medical devices and pa-
tient’s environment, as well as optimal antibiotic management.
Hospitalized elderly patients treated with antibiotics are at the
highest risk for CDI. FMT is highly promising treatment of CDI.
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